- $1.93bn
- $676.81m
- $548.51m
Billionaire Li Ka-shing’s Hutchmed in $608 mln health unit stake sales (updated)
Refile: China-based Hutchmed to divest stake in health unit for $608 million
Brief: Hutchmed China Ltd Will Receive $10 Mln Milestone Payment By Its Partner Takeda
HUTCHMED to Receive Milestone Payment from Takeda
Brief: Hutchmed (China) Says Breakthrough Therapy Designation For Orpathys And Tagrisso Combination
Breakthrough Therapy Designation in China
HUTCHMED and Innovent Announce ELUNATE Approval
Continued Inclusion of ORPATHYS in China NRDL
Brief: HUTCHMED Announces Launch By Takeda Of Fruzaqla® (Fruquintinib) In Japan
FRUZAQLA® Launched in Japan by Takeda
Appointment of Independent Non-executive Director
Clinical Data to be Presented at ASH and ESMO Asia
First Commercial Milestone Payment
Vesting of awards under the LTIP
Brief: Hutchmed Says Tagrisso Plus Orpathys Demonstrated Clinically Meaningful Response Rate In Lung Cancer Patients
Brief: Hutchmed (China) Says Takeda Receives Approval From Japan Ministry Of Health, Labour, Welfare
Brief: Hutchmed China Announces Partner Takeda's Japan Approval For Fruzaqla
Brief: UK'S MHRA Approves Fruquintinib To Treat Adult Patients With Metastatic Colorectal Cancer
US FDA sends warning letters to two Chinese firms for violating lab practices (updated)